Thesis Grading a multi-year investment in TG Therapeutics (TGTX)

In this episode of FOMO Investing, Brian O’Neill and Mikhail Bulchandani do a deep dive into one of Brian’s favorite stocks, TG Therapeutics (TGTX).  Brian outlines his multi-year investment thesis in TGTX, from its setbacks in oncology to its successful commercialization of Briumvi (ublituximab) for relapsing forms of multiple sclerosis.

What You’ll Learn:

• TG Therapeutics’ evolution to a successful commercial-stage biotech. 
• Practical investment strategies for investing in biotech companies like TGTX.
• Insights into the multiple sclerosis treatment landscape, and the growing market for anti-CD20 therapies, including Roche's Ocrevus, Novartis’s Kesimpta, and TG’s Briumvi.
• How Briumvi has been able to gain market traction.
• Upcoming catalysts for TG Therapeutics, including the potential for a label update to skip the initial dose, the potential to speed up infusions from 1 hour to 30-minutes, and the development of a subcutaneous formulation of Briumvi.
• A discussion about Bruton’s Tyrosine Kinase inhibitors (BTKi), a new class of disease modifying therapies in clinical trials for the treatment of MS.
• How TG Therapeutics has positioned itself as a compelling acquisition target.
• Brian revisits his February 8, 2024 article on TGTX, written when TG was at $14.32.  Recently shares have traded between $35 and $40.  
• Brian updates his forecast for when TG will achieve a $1 billion net product sales run-rate, and notes that the company today is considerably de-risked with market traction and net positive cash flows.

Links

• Brian’s February 8, 2024 article on TGTX
• The Evolution of Anti‑CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function
• Progress toward Mitigating Disability Progression in Multiple Sclerosis